UGT1A1 and Hyperbilirubinemia: Assessment of UGT1A1 *6,*27, and *28 alleles in 34 Japanese patients with CML receiving nilotinib found that UGT1A1 PMs (*6/*6, *6/*28, and *28/*28) had increased rates of hyperbilirubinemia and greater nilotinib dose reductions [81].